A drug most people associate with treating intestinal worms in livestock just cleared a significant hurdle in addiction medicine.
New research published in Neuropharmacology found that ivermectin, a widely used antiparasitic compound, dose-dependently reduced alcohol intake in rats that had been made dependent through a process called chronic intermittent ethanol vapor exposure.
That’s a big deal.
The study didn’t just show that a single dose dulled drinking behavior.
It showed that ivermectin worked through a specific brain mechanism, one that researchers believe plays a direct role in why people who struggle with alcohol use disorder keep drinking to avoid withdrawal symptoms.
The researchers focused on a brain region called the Central Amygdala, or CeA, which is widely known as a hub for the kind of negative emotional states that drive relapse.
When alcohol-dependent rats received ivermectin, electrical recordings from CeA brain slices showed enhanced GABAergic activity, meaning the calming, inhibitory chemical signals in that region got stronger.
That quieting of distress signals in the brain may be precisely what reduced the urge to drink.
This finding matters because most of the roughly 27.9 million Americans currently living with alcohol use disorder are not receiving medication to help them.
The Problem With What We Already Have
Right now, only three medications are FDA-approved to treat alcohol use disorder in the United States: naltrexone, acamprosate, and disulfiram.
All three have been around for decades.
All three come with meaningful limitations, including side effects, compliance issues, and inconsistent effectiveness across different patients.
Research shows that acamprosate and naltrexone reduce alcohol consumption and increase abstinence rates, but the effects appear modest, and evidence supporting disulfiram’s effectiveness is inconsistent.
That gap between what we have and what people actually need is enormous.
Among the 27.9 million people aged 12 or older with a past year alcohol use disorder, only 2.5%, or about 697,000 people, received any medication for their condition in the past year.
That is not a supply problem.
That is a science problem.
The medications available simply don’t work well enough for enough people.
Which is why the ivermectin research carries real weight, even if it is still at the preclinical stage.
But Here’s What Most People Get Wrong About Ivermectin
When most people hear the word “ivermectin,” they think of either livestock deworming or the heated political debates during the COVID pandemic.
The drug’s potential role in brain chemistry rarely enters the conversation.
That framing misses something important.
Ivermectin has been studied as a potential treatment for alcohol use disorder since at least the early 2000s.
The reason it keeps coming up is not random.
Researchers found that ivermectin, an FDA-approved semi-synthetic macrocyclic lactone, acts as a positive allosteric modulator of P2X4 receptors, essentially reducing or eliminating the inhibitory effects of ethanol on those receptors.
That mechanism is worth pausing on.
When someone drinks heavily and regularly, alcohol actively suppresses a receptor called P2X4, which is found throughout the brain’s reward and emotional regulation systems.
Studies show that alcohol-preferring rats have lower functional expression of the P2rx4 gene than non-preferring rats, suggesting an inverse relationship between alcohol intake and P2X4 receptor expression, and mice lacking the P2rx4 gene drink more alcohol than wildtype controls.
In other words, less P2X4 activity appears to be linked to more drinking.
Ivermectin steps in and essentially reverses that suppression.
It does not block the reward of alcohol outright the way naltrexone does.
It works by restoring the brain’s natural braking system, specifically in the region most responsible for withdrawal-induced distress.
That is a different approach entirely, and it may explain why it works in cases where other drugs fall short.
What the New Study Actually Found
The researchers used 32 alcohol-dependent rats that had already escalated their drinking following chronic ethanol vapor exposure.
This is an important detail.
These were not casual drinkers.
These animals had gone through a process designed to replicate the kind of negative reinforcement cycle seen in people with serious alcohol use disorder, where drinking shifts from pleasurable to necessary, driven by the need to escape withdrawal symptoms rather than to feel good.
In the 32 dependent rats, ivermectin dose-dependently reduced drinking, and the researchers stratified the animals into three groups: non-responders, mild responders, and high responders.
That stratification is meaningful.
It mirrors what clinicians see in humans, where some patients respond well to a given medication and others do not.
Electrophysiological recordings from CeA brain slices revealed that ivermectin differentially enhanced GABAergic inhibitory currents, with high-responders showing sustained increases in signaling frequency and selective amplitude reductions, while the other groups showed only transient increases.
The high-responders, the ones who cut their drinking most dramatically, also showed the most sustained changes in brain activity.
The conclusion the researchers drew is pointed: P2rx4 upregulation serves as a vulnerability marker for dependence-like behaviors, with ivermectin attenuating withdrawal-driven alcohol consumption by enhancing CeA GABAergic inhibition.
Translation: some individuals may be biologically predisposed to escalate alcohol use during withdrawal based on how their P2X4 genes are expressed.
And ivermectin may specifically help those individuals.
Why the Central Amygdala Is the Key
Most people have heard of the amygdala in the context of fear and anxiety.
The Central Amygdala is a subdivision of that region, and it plays a specific role in the stress-driven side of addiction.
When someone with alcohol use disorder is in withdrawal, the CeA becomes hyperactive.
That hyperactivity generates the anxiety, irritability, and emotional pain that push people back to drinking not for pleasure, but for relief.
This is the negative reinforcement loop that makes late-stage alcohol dependence so difficult to treat.
Most existing medications do not specifically target this loop.
Naltrexone primarily targets the reward side of drinking.
Acamprosate broadly attempts to normalize glutamate signaling.
Neither was designed with the specific stress-driven escalation phase in mind.
Ivermectin’s ability to calm CeA activity by enhancing GABA, the brain’s primary inhibitory signal, offers a mechanism that more directly addresses why dependent drinkers drink during withdrawal.
From the mechanistic standpoint, avermectins including ivermectin are positive modulators of purinergic P2X4 receptors, which belong to the P2X superfamily of cation-permeable ion channels gated by adenosine 5-triphosphate.
These channels are not just found in addiction circuits.
They are among the most abundantly expressed receptor types in the entire central nervous system.
That breadth of expression is part of why researchers believe this pathway has outsized potential as a therapeutic target.
The Genetic Angle
One of the most forward-looking parts of this study is what it implies about personalized medicine.
The researchers did not just test ivermectin on all the rats equally.
They used genetic prediction tools to estimate how each rat’s brain was likely expressing the P2rx4 gene before the experiment began.
Because this metric reflects baseline genetic predisposition rather than the post-dependent state, the researchers hypothesized that elevated predicted P2rx4 expression would be associated with an exacerbated escalation of ethanol self-administration following dependence-inducing exposure.
That hypothesis held up.
The animals with higher predicted P2rx4 expression showed more dramatic escalation after dependence and, critically, also showed the strongest response to ivermectin treatment.
This opens a genuinely exciting possibility in the clinic.
If a blood test or genetic screen could one day identify which patients have elevated P2rx4 expression, doctors could potentially predict who is most likely to spiral during withdrawal and who is most likely to respond to ivermectin-based treatment.
That kind of precision medicine approach to addiction is still largely theoretical for alcohol use disorder, but this study moves it closer to reality.
What About the Human Pilot Data?
Animal studies are a necessary first step, not a finish line.
But ivermectin has already been tested in at least one small human pilot study, which found it to be safe and tolerable in people with alcohol use disorder.
That does not mean it is ready for clinical use.
What it does mean is that the drug is not starting from zero in humans.
Researchers have found that the ability of ivermectin to reduce ethanol intake in mice strongly correlates with its ability to antagonize ethanol inhibition on P2X4 receptors in laboratory settings, and drug treatments did not cause signs of overt toxicity, tolerance, or dependence.
No toxicity.
No tolerance.
No dependence.
Those three words carry enormous weight in addiction pharmacology, where many treatments carry the risk of creating a new dependency or losing effectiveness over time.
The challenge that remains is pharmacokinetic.
The blood-brain barrier’s efflux activity limits how much ivermectin reaches and stays in the brain, with researchers finding that a protein called P-glycoprotein actively pumps the drug out of the central nervous system before it can achieve full effect.
That is a real obstacle.
But it is also a solvable engineering problem.
Research teams are already exploring drug combinations and structural modifications to improve ivermectin’s delivery to the brain.
The Bigger Picture
Every day, approximately 488 Americans die as a result of excessive alcohol use, with nearly half of those deaths occurring among adults aged 35 to 64.
Alcohol is not a niche health problem.
It is the most commonly misused substance in the world, embedded in almost every social and cultural context, and yet the medical toolkit for treating its most severe form has barely expanded in 30 years.
With over 54 million Americans in need of addiction treatment and only 23% receiving it, millions continue to suffer without support.
New mechanisms matter.
New targets matter.
And findings like this one, where an existing, already-approved compound works through a biologically coherent pathway to address one of the hardest parts of alcohol dependence, deserve more public attention than they typically receive.
The researchers behind this study were not chasing a headline.
They were building a case, piece by piece, that a repurposed antiparasitic drug might do something the last three decades of pharmaceutical development have not managed to do well.
Treat the brain state that actually drives relapse.
It is still early.
But the science is asking the right questions.
And sometimes, that is where everything changes.
